STRO.US Sutro Biopharma

Healthcare Biotechnology USA Stocks
8.92 USD
Close of Nov 17, 2026
7.15 43.85
Market cap
USD 148M
P/E
-
P/B
2.11x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is STRO.US undervalued?

Graham number

The Graham number of Sutro Biopharma cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sutro Biopharma fundamental analysis

No fundamental analysis for Sutro Biopharma yet.

Sutro Biopharma stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sutro Biopharma

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carci…

Full company profile